Abstract Library

#2897 Comparison of 68Ga-DOTATATE PET/CT for Assessment of Response to Peptide Receptor Radionuclide Therapy after 2 and 4 Cycles of 177Lu-DOTATATE: Preliminary Single Academic Center Experience

Introduction: Peptide receptor radionuclide therapy (PRRT) usually leads to stable rather than decreased lesion size in neuroendocrine tumors (NETs), therefore RECIST criteria are not used to assess early response to treatment.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Song H, Kunz P, Fisher G, Franc B, Moradi F,

Keywords: PRRT, 68Ga-DOTATATE PET/CT, Neuroendocrine tumor,

#2893 Prediction of Survival for Gastrointestinal Neuroendocrine Tumors: A Systematic Review of Clinical Tools

Introduction: Clinical prediction tools aggregate patient and disease information to predict outcomes. Little is known about gastrointestinal neuroendocrine tumors (GI-NET) prediction tools accuracy and utility.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hallet J

Authors: Hallet J, Ho G, Beyfuss K, Chan D, Law C,

Keywords: neuroendocrine, gastrointestinal, prediction, risk score, survival,

#2884 An Infectious Diseases Specialist NET Patient Looks at Management of NETs

Introduction: Medical specialties may develop practices minimally influenced by other specialties.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Schmid G,

Keywords: neuroendocrine, everolimus, somatostatin analogue, drug levels,

#2866 Extrahepatic 68Ga-DOTATATE-Avid Tumor Volume and Serum Chromogranin A Predict Short-Term Outcome of 177Lu-DOTATATE in Late-Stage Metastatic Gastroenteropancreatic Neuroendocrine Tumors

Introduction: 177Lu-DOTATATE is an effective therapy for somatostatin receptor-positive neuroendocrine tumors (NETs). Often enough 177Lu-DOTATATE is used as the last treatment resort in advanced NET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Song H, Kunz P, Franc B, Moradi F, Fisher G,

Keywords: 177Lu-DOTATATE, PRRT, 68Ga-DOTATATE PET, Chromogranin A, 68Ga-DOTATATE avid tumor volume,

#2269 Can Insulin-Like Growth Factor 1 (IGF-1), IGF-1 Receptor, Connective Tissue Growth Factor and Ki-67 Labelling Index Have a Prognostic Role in Pulmonary Carcinoids?

Introduction: Altered expression of Insulin-like Growth Factor-1 (IGF-1), its receptor (IGF-1R), Connective Tissue Growth Factor (CTGF) and Hypoxia Factor-1 (HIF-1), has been implicated in tumorigenesis. These factors have not been studied systematically in Pulmonary Carcinoids (PCs).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Tsolakis A, Kanakis G, Grimelius G, Papaioannou D, Kaltsas G,

Keywords: IGF-1, IGF-1R, CTGF, HIF-1, Ki-67,